Document is current
Any future updates will be listed below
-
Authors
MacDonald, Rachael https://orcid.org/0009-0005-1725-4140
Hex, Nick https://orcid.org/0000-0002-6181-9429
Uzdzinska, Barbara https://orcid.org/0009-0004-3284-3886
Umpleby, Beth https://orcid.org/0009-0001-2218-8054
Pocock, Jessica https://orcid.org/0009-0005-5552-1588
Hawthorne, A. Barney https://orcid.org/0000-0002-8768-4550
Pollok, Richard https://orcid.org/0000-0001-6452-6763
Blackwell, Jonathan https://orcid.org/0000-0003-4278-3720
Din, Shahida https://orcid.org/0000-0003-2855-3400
- License Information
-
More Information
Article History
Received: 23 January 2026
Accepted: 26 June 2026
First Online: 8 July 2026
Declarations
:
: Participation in the 2023 UK IBD Patient Survey was voluntary. Completion of the survey was taken as informed consent to participate, and no identifiable patient data was stored, so all responses were anonymous for analysis and publication. Ethics approval was not required for NHS service improvement surveys that are anonymous.
: Participation in the 2023 UK IBD Patient Survey was voluntary and respondents were informed that anonymised, aggregate results would be published. Completion of the survey was taken as informed consent to participate, and all responses were anonymised prior to analysis and publication.
: SD is Chair of British Society of Gastroenterology Inflammatory Bowel Disease Committee and MHRA Gastroenterology, Rheumatology, Immunology & Dermatology Expert Advisory Group. Reports grants from Crohn’s & Colitis UK, The Helmsley Charitable Trust, Edinburgh and Lothians Health Foundation, Pathological Society of Great Britain and Northern Ireland, and Lord Leonard and Lady Estelle Wolfson Foundation; consultant to AbbVie, Eli Lilly, honoraria or speaker fees from Janssen, Takeda, Ferring, Dr Falk, and AbbVie and meeting and travel grants from AbbVie, Janssen, Takeda, Lilly, and Dr Falk.
